請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/91669
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張美惠 | zh_TW |
dc.contributor.advisor | Mei-Hwei Chang | en |
dc.contributor.author | 張凱琪 | zh_TW |
dc.contributor.author | Kai-Chi Chang | en |
dc.date.accessioned | 2024-02-20T16:28:24Z | - |
dc.date.available | 2024-02-21 | - |
dc.date.copyright | 2024-02-20 | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-01-31 | - |
dc.identifier.citation | 1.Dusheiko G, Agarwal K, Maini MK. New Approaches to Chronic Hepatitis B. N Engl J Med. 2023 Jan 5;388(1):55-69.
2.GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829. 3.Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, Séguy N, Rewari BB, Chan PL, Le LV, Doherty M, Luhmann N, Easterbrook P, Dirac M, de Martel C, Nayagam S, Hallett TB, Vickerman P, Razavi H, Lesi O, Low-Beer D. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. 4.WHO. Global health sector strategy on viral hepatitis 2016-2021- towards ending viral hepatitis. June 2016. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06- eng.pdf. 5.Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975 Apr 10;292(15):771-4. 6.Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022 Jan;22(1):19-32. 7.Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, Chen KP. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis. 1982 Aug;146(2):198-204. 8.Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol. 1983 Feb;117(2):213-22. 9.Feret E, Larouze B, Diop B, Sow M, London WT, Blumberg BS. Epidemiology of hepatitis B virus infection in the rural community of Tip, Senegal. Am J Epidemiol. 1987 Jan;125(1):140-9. 10.Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730–5. 11.Ni YH, Chang MH, Jan CF, et al. Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. Clin Gastroenterol Hepatol 2016; 14:1324–30. 12.Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276:906–8. 13.Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135:796–800. 14.Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287–93. 15.Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301–7. 16.Chang MH, Chen TH, Hsu HM, et al; Taiwan Childhood HCC Study Group. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005; 11:7953–7. 17.Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855–9. 18.Chang KC, Chang MH, Chen HL, Wu JF, Chang CH, Hsu HY, Ni YH. Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 Years: Moving Toward the Eradication of HBV. J Infect Dis. 2022 Feb 1;225(3):431-435. 19.Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020 Feb 26;33(2):e00046-19. 20.Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, Huang FC, Wu SF, Chen SC, Wen WH, Chu CH, Ni YH, Hsu HY, Tsai PL, Chiang CL, Shyu MK, Lee PI, Chang FY, Chang MH. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012 Apr;142(4):773-781.e2. 21.Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, Wu SF, Lee CM, Yang SS, Chu HC, Wang TE, Chen BW, Chuang WL, Soon MS, Lin CY, Chiou ST, Kuo HS, Chen DS; Taiwan Hepatoma Study Group. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology. 2016 Sep;151(3):472-480.e1. 22.Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL. Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology. 2015 Apr;61(4):1183-91. 23.Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006 Jan;44(1):39-46. 24.Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, Chen PJ, Chen DS. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology. 1992 May;15(5):770-6. 25.Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol. 1998 Feb 15;160(4):2013-21. 26.Tian Y, Kuo CF, Akbari O, Ou JH. Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. Immunity. 2016 May 17;44(5):1204-14. 27.Visvanathan K, Dusheiko G, Giles M, Wong ML, Phung N, Walker S, Le S, Lim SG, Gane E, Ngu M, Hardikar W, Cowie B, Bowden S, Strasser S, Levy M, Sasaduesz J.Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. Gut. 2016 Feb;65(2):340-50. 28.Hsu HY, Chang MH. Hepatitis B Virus Infection and the Progress toward its Elimination. J Pediatr. 2019 Feb;205:12-20. 29.Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. 30.Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009 Feb;16(2):94-103. 31.Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011 Dec;55(6):1215-21. 32.Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2017. Wilmington, NC: Registry Coordinating Center; 2017. 33.Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, Hu JJ, Lin HH, Zhao LL, Mu SC, Lai MW, Lee CL, Lin HM, Tsai MS, Hsu JJ, Chen DS, Chan KA, Chang MH; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT Study); Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV PreMIT Study. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015 Aug;62(2):375-86. 34.Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, Chen ZM, Cui GL, Li W, Zhang DW, Li J, Lv J, Li ZQ, Liang HX, Sun CY, Pan YJ, Liu YM, Wang FS. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin Infect Dis. 2021 Nov 2;73(9):e3324-e3332. 35.Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, Holdaway S, Samarasinghe D, Jackson K, Locarnini SA, Levy MT. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014 Sep;61(3):502-7. 36.Lee BH. Commentary on: "Comprehensive molecular characterization of papillary renal-cell carcinoma." Cancer Genome Atlas Research Network.: N Engl J Med. 2016 Jan 14;374(2):135-45. Urol Oncol. 2017 Sep;35(9):578-579. 37.Chang KC, Chang MH, Lee CN, Chang CH, Wu JF, Ni YH, Wen WH, Shyu MK, Lai MW, Chen SM, Hu JJ, Lin HH, Hsu JJ, Mu SC, Lin YC, Liu CJ, Chen DS, Lin LH, Chen HL; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study). Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. Aliment Pharmacol Ther. 2019 Aug;50(3):306-316. 38.Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. 39.Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68. 40.Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):239-48. 41.McNab F, Mayer-Barber K, Sher A, Wack A, O''Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87-103. 42.Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat Rev Immunol. 2011;11(10):645-657. 43.Megahed FAK, Zhou X, Sun P. The interactions between HBV and the innate immunity of hepatocytes. Viruses. 2020;12(3):285-299. 44.Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014;11:22. 45.Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009 Apr;49(4):1132-40. 46.Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012 Dec;61(12):1754-64. 47.Hong M, Bertoletti A. Tolerance and immunity to pathogens in early life: insights from HBV infection. Semin Immunopathol. 2017;39(6):643-652. 48.Lebosse F, Testoni B, Fresquet J, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J Hepatol. 2017;66(5):897-909. 49.Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts. J Biomed Sci. 2015 Oct 20;22:92. 50.European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. 51.Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodríguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, Sriprayoon T, Chong Y, Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology. 2019 Feb;156(3):635-646.e9. 52.Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a longterm follow-up. Hepatology. 2007;45:1187–1192. 53.Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010 Feb;51(2):435-44. 54.Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010 Oct;55(10):2727-34. 55.Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim DY, Hwang SG, Rim KS, Chon CY, Han KH, Park JY. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011 May;53(5):1486-93. 56.Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, Lai ST, Wong WM, Lai LS, Poon RT, Lo CM, Fan ST, Lau GK; Hong Kong Liver Fibrosis Study Group. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007 Sep;46(3):690-8. 57.Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007 Dec;1(4):415-30. 58.Wu JF, Chen CH, Hsieh RP, Shih HH, Chen YH, Li CR, Chiang CY, Shau WY, Ni YH, Chen HL, Hsu HY, Chang MH. HLA typing associated with hepatitis B E antigen seroconversion in children with chronic hepatitis B virus infection: a long-term prospective sibling cohort study in Taiwan. J Pediatr. 2006 May;148(5):647-651. 59.Wu JF, Tsai WY, Hsu HY, Ni YH, Chen HL, Tsuei DJ, Chang MH. Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men. Gastroenterology. 2010 Mar;138(3):942-8.e1. 60.Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY, Chang MH. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology. 2010 Jan;138(1):165-72.e1-3. 61.Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989 Sep 9;2(8663):588-91. 62.Ni YH, Chang MH, Chen PJ, Tsai KS, Hsu HY, Chen HL, Tsuei DJ, Chen DS. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology. 2007 Jun;132(7):2340-5. 63.Lim SG, Cheng Y, Guindon S, Seet BL, Lee LY, Hu P, et al. Viral quasi-species evolution during hepatitis B e Antigen seroconversion. Gastroenterology 2007;133:951-958. 64.Vanwolleghem T, Adomati T, Van Hees S, Janssen HLA. Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV. JHEP Rep. 2021 Nov 19;4(2):100398 65.Yen CJ, Yang ST, Chen RY, Huang W, Chayama K, Lee MH, Yang SJ, Lai HS, Yen HY, Hsiao YW, Wang JM, Lin YJ, Hung LY. Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis. J Biomed Sci. 2019 Jun 6;26(1):44. 66.Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013 Feb;13(2):123-35. 67.Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016 Apr;64(1 Suppl):S84-S101. 68.Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol. 2010;185(2):1158-1168. 69.Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem. 2005 Apr 29;280(17):16739-47. 70.Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J, Peppa D, Gilson RJ, Gehring A, Bertoletti A, Maini MK. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest. 2008 May;118(5):1835-45. 71.Wu JF, Su YR, Chen CH, Chen HL, Ni YH, Hsu HY, Wang JL, Chang MH. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):97-100. 72.Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS, Chen PJ. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004 Oct;41(4):659-66. 73.Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476. 74.Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J Hepatol. 2017 May;66(5):897-909. 75.Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol. 2009 Oct;10(10):1065-72. 76.Bertoletti A, Hong M. Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation. Front Immunol. 2014 Sep 23;5:441. 77.Huang B, Li J, Zhang X, Zhao Q, Lu M, Lv Y. RIG-1 and MDA-5 signaling pathways contribute to IFN-β production and viral replication in porcine circovirus virus type 2-infected PK-15 cells in vitro. Vet Microbiol. 2017 Nov;211:36-42. 78.Cao Z, Xia Z, Zhou Y, Yang X, Hao H, Peng N, Liu S, Zhu Y. Methylcrotonoyl-CoA carboxylase 1 potentiates RLR-induced NF-κB signaling by targeting MAVS complex. Sci Rep. 2016 Sep 15;6:33557. 79.Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell. 2011 Aug 5;146(3):448-61. 80.Wang X, Li Y, Mao A, Li C, Li Y, Tien P. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol. 2010 Sep;7(5):341-8. 81.Su WJ, Chen SF, Yang CH, Chuang PH, Chang HF, Chang MH. The Impact of Universal Infant Hepatitis B Immunization on Reducing the Hepatitis B Carrier Rate in Pregnant Women. J Infect Dis. 2019 Aug 30;220(7):1118-1126. 82.Banatvala JE, Van Damme P. Hepatitis B vaccine -- do we need boosters? J Viral Hepat. 2003 Jan;10(1):1-6. 83.Candotti D, Assennato SM, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019 Feb;68(2):313-321. 84.Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):319-33. 85.Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012 Feb;19(2):e18-25.91. 86.King SM; American Academy of Pediatrics Committee on Pediatric AIDS; American Academy of Pediatrics Infectious Diseases and Immunization Committee. Evaluation and treatment of the human immunodeficiency virus-1--exposed infant. Pediatrics. 2004 Aug;114(2):497-505. 87.Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013 Jul;59(1):24-30. 88.Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, Jiang H; China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med. 2016 Jun 16;374(24):2324-34. 89.Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R, Tiongson BC, Zhang H, Pan CQ. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther. 2019 Jan;49(2):211-217. 90.COMMITTEE ON INFECTIOUS DISEASES; COMMITTEE ON FETUS AND NEWBORN. Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth. Pediatrics. 2017 Sep;140(3):e20171870. 91.World Health Organization. Hepatitis B. Fact Sheet 204. 2017; http://www.who.int/mediacentre/factsheets/fs204/en/. 92.Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr. 1998 Sep;133(3):374-7. 93.Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX, Liu ZH, Wang FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol. 2002 May;67(1):20-6. 94.Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009 Jan;29 Suppl 1:133-9. 95.Papaevangelou V. Perinatal HBV viremia in newborns of HBsAg(+) mothers is a transient phenomenon that does not necessarily imply HBV infection 96.Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus. J Infect. 2013 May;66(5):447-52. 97.Lao TT. Immune persistence after hepatitis B vaccination in infancy - Fact or fancy? Hum Vaccin Immunother. 2016 May 3;12(5):1172-6. 98.Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004 Apr;39(4):978-88. 99.Sakai A, Noguchi E, Fukushima T, Tagawa M, Iwabuchi A, Kita M, Kakisaka K, Miyasaka A, Takikawa Y, Sumazaki R. Identification of amino acids in antigen-binding site of class II HLA proteins independently associated with hepatitis B vaccine response. Vaccine. 2017 Jan 23;35(4):703-710. 100.McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010 Aug;14(3):381-96. 101.Faure-Dupuy S, Lucifora J, Durantel D. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. Viruses. 2017 Apr 28;9(5):95. 102.Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol. 2001 Oct;36(10):651-60. 103.Yeh CT. Hepatitis B virus X protein: searching for a role in hepatocarcinogenesis. J Gastroenterol Hepatol. 2000 Apr;15(4):339-41. 104.Li SK, Ho SF, Tsui KW, Fung KP, Waye MY. Identification of functionally important amino acid residues in the mitochondria targeting sequence of hepatitis B virus X protein. Virology. 2008 Nov 10;381(1):81-8. 105.Wang F, Shen F, Wang Y, Li Z, Chen J, Yuan Z. Residues Asn118 and Glu119 of hepatitis B virus X protein are critical for HBx-mediated inhibition of RIG-I-MAVS signaling. Virology. 2020 Jan 2;539:92-103. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/91669 | - |
dc.description.abstract | 世界衛生大會制訂一項全球衛生策略,希望在2030年可以根除病毒性肝炎。在所有根除B型肝炎的方法中,全面接種B型肝炎疫苗是預防感染B型肝炎最具成本效益的方法。台灣作為推動全面B型肝炎疫苗先驅,經過30多年的演進,成功使B型肝炎盛行率大幅減低。這項成功可以歸因於疫苗接種高覆蓋率和全面的B型肝炎病毒篩檢,共同建立了強大的防禦網絡。我們進行了一個大規模研究,徹底探究後疫苗時代所有可能的慢性B型肝炎傳播情況。從台北都會區招募的1611名1歲到59歲的受試者中,我們發現疫苗接種後世代的B型肝炎表面抗原跟B型肝炎核心抗體的盛行率皆遠低於疫苗接種前世代(0.4% vs 7.7%、2.2% vs 50.8% ,P < .0001)。另外值得注意的是,疫苗接種後世代中,那些被發現B型肝炎表面抗原陽性的個案都是由B型肝炎帶原母親所生。
除了全面接種B型肝炎疫苗以外,給予懷孕母親抗病毒藥物治療,為另一個對抗B型肝炎垂直感染的重要方式。經由我們第一部分的研究,確認母嬰垂直感染是B型肝炎感染的主要傳染途徑、也是為施打疫苗卻發生突破性感染的主要原因。若懷孕母親具有B型肝炎高病毒量,或e抗原陽性,代表母親體內病毒正在大量複製,則會增加突破性感染的發生率。利用抗病毒藥物治療懷孕婦女可以降低其體內的病毒量,進而減低母嬰傳染的風險。然而,這些嬰兒出生時體內是否測得到B型肝炎病毒的存在,而這對隨後的慢性B型肝炎風險到底有何影響仍不清楚。為了回答這個問題,我們招募了201名慢性B型肝炎感染並且為高病毒量的孕婦,其中有110人在第三孕程接受惠立妥(tenofovir)治療,其餘的孕婦則維持常規孕程追蹤,並未特別服用抗病毒藥。在總共208名誕生的寶寶中,惠立妥組的新生兒,其體內測得B型肝炎去氧核醣核酸(DNA)陽性率比較媽媽沒有接受惠立妥組的新生兒低(5.22%對30.11%,P < .0001),並在6個月(1.74%對11.83%,P = .003)和12個月(1.74%對10.75%,P = .007)的B型肝炎表面抗原陽性率也比較低。此外,我們發現新生兒B型肝炎病毒DNA陽性與否,在多變量分析中是預測兒童慢性B型肝炎感染的有效獨立預測因子(勝算比odds ratio = 61.89, P = .0002)。 延續母嬰垂直傳染的議題,慢性B型肝炎感染的懷孕母親若處於B型肝炎e抗原陽性的病毒活躍複製期,將病毒傳染給寶寶的機率大幅增加。此段e抗原陽性時期稱之為免疫耐受期,而它是慢性B型肝炎感染自然史中,佔據兒童、青少年、到年輕成人數十年光陰的一個階段。若我們能對免疫耐受期增加更多理解,或許能預測哪些慢性B型肝炎感染個案,當成為懷孕母親時傳染病毒給寶寶的機率較低,而哪些人又較高。 從免疫耐受期過渡到免疫廓清期(immune clearance phase),甚至成功達到B型肝炎e抗原陰轉,這些現象暗示著人類宿主的免疫力復甦,通常對長期病程的預後有益。然而,在慢性B型肝炎感染自然史中,調控免疫耐受期的機制仍然不明。粒線體抗病毒信號蛋白質(MAVS, Mitochondrial Antiviral Signaling Protein)是一個負責傳遞訊息向下,推動乙型干擾素(IFN-β)順利產生的重要物質。B型肝炎病毒X蛋白(HBx protein)已被報導會透過減少粒線體抗病毒信號蛋白質來破壞下游的乙型干擾素的生成,進而可能損害後續對抗B型肝炎病毒的後天免疫系統 (adaptive immune system)。我們分析了慢性B型肝炎患者基因變異對免疫耐受期的影響,發現臨床上帶有HBx R87G、I127V以及R87G+I127V雙重突變感染株的患者較容易突破免疫耐受期。 接著,我們進行細胞轉染,將帶有B型肝炎病毒X基因R87G和I127V變異的片段送入肝細胞株中,並且發現細胞內、外偵測到的乙型干擾素皆有顯著上升。再者,我們偵測到一旦B型肝炎病毒X蛋白出現R87G和I127V的變異,粒線體抗病毒信號蛋白質會被野生型B型肝炎病毒X蛋白附著並且進行泛素化 (ubiquitination)分解的作用將會被抵銷,此舉有助於保留住粒線體抗病毒信號蛋白質。由此推斷特定的B型肝炎病毒X基因的突變,在B型肝炎病毒跟宿主的免疫系統交互作用中扮演重要的角色,它會往下恢復乙型干擾素的產生。這個過程或許有助於逆轉原本免疫系統耗竭的情況,促進免疫耐受期的突破。 根除B型肝炎感染,除了給予患者核苷/核苷酸類似物(nucleos(t)ide analogues) 治療以外,全面讓新生兒接受B型肝炎疫苗接種、以及在第三孕程給予高風險B型肝炎帶原母親抗病毒藥物,皆有助降低傳播機率。另外,深入了解慢性B型肝炎感染的自然病程中的演進、並且探索內部的潛在機制,都有助於我們制定更全面的B型肝炎感染者的篩檢和監測,並為他們提供適當的後續追蹤和照護。 | zh_TW |
dc.description.abstract | The World Health Assembly is addressing a Global Health Sector Strategy aimed at eliminating viral hepatitis by the year 2030. Of all the methods available for eradicating hepatitis B virus (HBV) infection, universal vaccination stands out as the most cost-effective approach for preventing new infections. Taiwan, as the pioneer in establishing universal HBV immunization, has demonstrated a remarkable decline in the prevalence of HBV infection over the past three decades. This success can be attributed to high vaccination coverage and comprehensive HBV screening, which have collectively contributed to the establishment of a robust healthcare network.
We conducted an extended survey to thoroughly investigate all conceivable transmission of chronic hepatitis B (CHB) infection in the post-vaccination era. Among the 1611 subjects recruited from Taipei metropolitan area, we found the prevalences of HBsAg and anti-HBc in the vaccinated birth cohort were lower than those born before 1984 (0.4% vs 7.7%, and 2.2% vs 50.8%, P < .0001; respectively). Notably, all three vaccine-failure carriers all were born to HBsAg carrier mothers. Mother-to-infant transmission (MTIT) is the primary avenue for HBV acquisition, accounting for the majority of instances of immunoprophylaxis failure. Maternal High viral load or positive hepatitis B e antigen, indicating active viral replication, both contribute to breakthrough infection. The utilization of maternal antiviral therapy can effectively reduce the HBV viral load in mothers with high viremia, consequently diminishing the risk of MTIT. Nevertheless, the impact of neonatal viremia in these infants on subsequent HBV infection remains unclear. To answer this question, we recruited 201 HBV carrier pregnant mothers who had high viral load, and 110 of them received tenofovir during the third trimester. Of the 208 children, those in the tenofovir group had a lower rate of neonatal HBV DNA seropositivity at birth (5.22% versus 30.11%, P < .0001), and HBsAg seropositivity at 6 months (1.74% versus 11.83%, P = .003) and 12 months (1.74% versus 10.75%, P = .007). In addition, we found neonatal HBV DNA positivity was a strong independent influence variable in multivariate analysis to predict children’s CHB infection (odds ratio = 61.89, P = .0002). Transitioning from the immune-tolerant phase to the immune clearance phase, and even achieving HBeAg seroconversion, which implies host immune restoration, usually confers a favorable prognosis. However, the immunologic mechanisms underlying the immune-tolerant phase of CHB infection remain unknown. The Hepatitis B virus X (HBx) protein disrupts IFN-β induction by downregulating mitochondrial antiviral signaling protein (MAVS) and may impair subsequent HBV-specific adaptive immunity. We analyzed the impacts of genetic variability of CHB patients on the immune-tolerant phase, and found patients carrying HBx R87G, I127V, and R87G+I127V double mutations exhibited higher cumulative incidences of immune-tolerant phase breakthrough. Cells transfected with HBx R87G and I127V mutants and pHBV1.3-B6.3 replicons containing the HBx R87G and I127V mutations exhibited statistically increased level of IFN-β as well. HBx R87G and I127V mutants also helped to preserve Flag-MAVS, by diminishing its ubiquitination which was stimulated by HA-HBx wild-type. Specific HBx mutants are implicated in the interaction between HBV and components of host innate immunity, rescuing the production of IFN-β. This may be helpful to restore exhausted immune responses to achieve immune-tolerant phase breakthrough. Gaining a deeper understanding of the behaviors and potential mechanisms inherent in the natural course of HBV infection can help us to set a more comprehensive screening and monitoring protocol for HBV-infected persons, and provide them with appropriate follow-up and care. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-02-20T16:28:24Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2024-02-20T16:28:24Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 中文摘要 iii 英文摘要 v 目次 viii 圖次 ix 表次 xiv 第一章 緒論 1 第二章 研究方法與材料 12 第三章 結果 23 第四章 討論 42 第五章 展望 53 第六章 參考文獻 56 第七章 圖表 71 第八章 附錄 100 | - |
dc.language.iso | en | - |
dc.title | 邁向B型肝炎病毒根除之路:透過全面嬰兒B型肝炎疫苗接種和給予懷孕母親惠立妥治療,並探索HBx 基因變異對免疫耐受期的影響 | zh_TW |
dc.title | Moving Toward the Eradication of Hepatitis B virus: By Universal Infant HBV Vaccination and Maternal Tenofovir Treatment, and Exploring the Role of HBx Variants on Immune-tolerant phase | en |
dc.type | Thesis | - |
dc.date.schoolyear | 112-1 | - |
dc.description.degree | 博士 | - |
dc.contributor.coadvisor | 倪衍玄 | zh_TW |
dc.contributor.coadvisor | Yen-Hsuan Ni | en |
dc.contributor.oralexamcommittee | 許宏遠;高嘉宏;賴明瑋;楊燿榮 | zh_TW |
dc.contributor.oralexamcommittee | Hong-Yuan Hsu;Jia-Horng Kao;Ming-Wei Lai;Yao-Jong Yang | en |
dc.subject.keyword | B型肝炎,全面B型肝炎疫苗接種,母子傳染,惠立妥,免疫耐受期,B型肝炎病毒X基因, | zh_TW |
dc.subject.keyword | hepatitis B virus,universal hepatitis B vaccination,mother-to-infant transmission,tenofovir,immune-tolerant phase,Hepatitis B virus X, | en |
dc.relation.page | 104 | - |
dc.identifier.doi | 10.6342/NTU202400359 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2024-02-01 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 臨床醫學研究所 | - |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-112-1.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 3.4 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。